[go: up one dir, main page]

DE69828801D1 - Peptide abgeleitet vom bindungs (g) protein des respiratorisches synzytialvirus - Google Patents

Peptide abgeleitet vom bindungs (g) protein des respiratorisches synzytialvirus

Info

Publication number
DE69828801D1
DE69828801D1 DE69828801T DE69828801T DE69828801D1 DE 69828801 D1 DE69828801 D1 DE 69828801D1 DE 69828801 T DE69828801 T DE 69828801T DE 69828801 T DE69828801 T DE 69828801T DE 69828801 D1 DE69828801 D1 DE 69828801D1
Authority
DE
Germany
Prior art keywords
protein
rsv
altered
synzytialvirus
respiratory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69828801T
Other languages
English (en)
Other versions
DE69828801T2 (de
Inventor
E Hancock
W Tebbey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Wyeth LLC
Original Assignee
Wyeth Holdings LLC
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Holdings LLC, Wyeth LLC filed Critical Wyeth Holdings LLC
Publication of DE69828801D1 publication Critical patent/DE69828801D1/de
Application granted granted Critical
Publication of DE69828801T2 publication Critical patent/DE69828801T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69828801T 1997-09-19 1998-09-17 Peptide, abgeleitet vom angelagerten g-protein des respiratory syncytial virus Expired - Fee Related DE69828801T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5968497P 1997-09-19 1997-09-19
US59684P 1997-09-19
US8486398P 1998-05-08 1998-05-08
US84863P 1998-05-08
PCT/US1998/019656 WO1999014334A1 (en) 1997-09-19 1998-09-17 Peptides derived from the attachment (g) protein of respiratory syncytial virus

Publications (2)

Publication Number Publication Date
DE69828801D1 true DE69828801D1 (de) 2005-03-03
DE69828801T2 DE69828801T2 (de) 2005-07-14

Family

ID=26739056

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69828801T Expired - Fee Related DE69828801T2 (de) 1997-09-19 1998-09-17 Peptide, abgeleitet vom angelagerten g-protein des respiratory syncytial virus

Country Status (13)

Country Link
EP (1) EP1015595B1 (de)
JP (1) JP2001516583A (de)
KR (1) KR100550132B1 (de)
CN (1) CN1259422C (de)
AT (1) ATE287957T1 (de)
AU (1) AU751022B2 (de)
BR (1) BR9812240A (de)
CA (1) CA2302833C (de)
CY (1) CY1105010T1 (de)
DE (1) DE69828801T2 (de)
ES (1) ES2236946T3 (de)
PT (1) PT1015595E (de)
WO (1) WO1999014334A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60136381D1 (de) 2000-10-18 2008-12-11 Us Gov Health & Human Serv Zusammensetzungen und verfahren zur modulierung von rsv-infektionen und -immunität
AUPR520201A0 (en) * 2001-05-23 2001-06-14 Commonwealth Scientific And Industrial Research Organisation Antiviral compounds
NL1019228C1 (nl) 2001-10-25 2003-04-28 Duynstee Holding B V Verbeterd gecombineerd ophang- en verlichtingssysteem voor bijvoorbeeld schilderijen e.d.
US6667327B2 (en) 2002-02-04 2003-12-23 Hoffmann-La Roche Inc. Pyridine amido derivatives
DE10219219A1 (de) 2002-04-29 2003-11-06 Tampoflex Gmbh Druckanlage
WO2004092207A2 (en) * 2003-04-16 2004-10-28 Algonomics N.V. Respiratory syncytial virus (rsv) peptides
US7368537B2 (en) * 2003-07-15 2008-05-06 Id Biomedical Corporation Of Quebec Subunit vaccine against respiratory syncytial virus infection
CN100441188C (zh) 2003-10-23 2008-12-10 弗·哈夫曼-拉罗切有限公司 作为mao－b抑制剂的苯并氮杂衍生物
WO2006004874A1 (en) * 2004-06-30 2006-01-12 Wyeth Holdings Corporation Recombinant rsv strains with altered g protein
WO2008114149A2 (en) * 2007-03-21 2008-09-25 Id Biomedical Corporation Of Quebec Chimeric antigens
CN101952321B (zh) 2007-12-24 2016-05-11 葛兰素史密斯克莱生物公司 重组rsv抗原
UA111141C2 (uk) 2009-06-24 2016-04-11 Глаксосмітклайн Байолоджікалз С.А. Рекомбінантні антигени рсв
AU2010264686A1 (en) 2009-06-24 2012-01-19 Glaxosmithkline Biologicals S.A. Vaccine
ES2918381T3 (es) 2009-07-15 2022-07-15 Glaxosmithkline Biologicals Sa Composiciones de proteína F de VRS y métodos para producir las mismas
WO2011007961A2 (en) * 2009-07-17 2011-01-20 Industry Academic Cooperation Foundation, Hallym University Immunostimulatory compositions comprising liposome-encapsulated oligonucleotides and epitpoes
CA2770304C (en) 2009-08-04 2019-11-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention Anti-rsv immunogens and methods of immunization
AU2012255971A1 (en) 2011-05-13 2013-05-02 Novartis Ag Pre-fusion RSV F antigens
WO2020212576A1 (en) * 2019-04-18 2020-10-22 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Biological and synthetic molecules inhibiting respiratory syncytial virus infection

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2726577B1 (fr) * 1994-11-07 1997-01-31 Pf Medicament Procede d'obtention d'un peptide derive du virus respiratoire syncitial, polypeptide et bacterie l'exprimant, et leurs applications a titre de medicament
AUPO026596A0 (en) * 1996-06-05 1996-06-27 Biomolecular Research Institute Limited Viral peptide
AU722494C (en) * 1996-06-05 2007-03-29 Commonwealth Scientific And Industrial Research Organisation Viral peptides with structural homology to protein G of respiratory syncytial virus

Also Published As

Publication number Publication date
ATE287957T1 (de) 2005-02-15
CY1105010T1 (el) 2010-03-03
KR20010030620A (ko) 2001-04-16
JP2001516583A (ja) 2001-10-02
ES2236946T3 (es) 2005-07-16
CA2302833A1 (en) 1999-03-25
CA2302833C (en) 2007-05-08
PT1015595E (pt) 2005-05-31
AU9572598A (en) 1999-04-05
EP1015595B1 (de) 2005-01-26
AU751022B2 (en) 2002-08-08
DE69828801T2 (de) 2005-07-14
EP1015595A1 (de) 2000-07-05
CN1259422C (zh) 2006-06-14
BR9812240A (pt) 2000-07-18
KR100550132B1 (ko) 2006-02-08
CN1322250A (zh) 2001-11-14
WO1999014334A1 (en) 1999-03-25

Similar Documents

Publication Publication Date Title
DE69828801D1 (de) Peptide abgeleitet vom bindungs (g) protein des respiratorisches synzytialvirus
ATE392904T1 (de) Pharmazeutische zusammensetzung zur immunstimulation und zur zubereitung von impfstoffen enthaltend ein antigen, und als adjuvantien ein immunogenes oligodesoxynukleotid und ein polykationisches polypeptid
WO2005021707A3 (en) Severe acute respiratory syndrome dna vaccine compositions and methods of use
ATE250937T1 (de) Chitosan und influenza-antigen(e) enthaltende impfstoff-zubereitungen zur verabreichung durch eine mukosa
WO2002048183A3 (en) Compositions of peptide crystals
ATE306931T1 (de) Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer
BR9909915A (pt) Composições adjuvantes
MY129566A (en) A hypoallergenic composition containing tolerogenic peptides inducing oral tolerance
DK1090033T3 (da) Partikler af HCV-kappeproteiner: Anvendelse til vaccination
EP2011510A3 (de) Pharmazeutische Zusammensetzungen, die immunologisch aktive Herpes simplex Virus Proteinfragmente enthalten
IS4518A (is) Nýtt lyfjaform fyrir bóluefni
CA2224724A1 (en) Subunit vaccine against flavivirus infection
WO2002032923A3 (en) Improved formulations using heat shock/stress protein-peptide complexes
IS2670B (is) Bóluefni og notkun þar á til meðhöndlunar á blandaðri hreyfitaugahrörnun
JP2001516583A5 (de)
AU5577201A (en) Immunogenic pneumococcal protein and vaccine compositions thereof
EE9800334A (et) Helicobacter pylor' iga seotud nukleiinhapete ja aminohapete järjestused ja nendest tuletatud vaktsiinikompositsioonid
ATE356140T1 (de) Gd3 mimetische peptide
WO1999053950A3 (en) Live vaccines and methods of treatment therewith
ATE371737T1 (de) Proteaseresistente flint-analoge
NZ507983A (en) A polypeptide comprising the amino acid of an n- terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof
DE60033414D1 (de) Allergievakzine sowie ihre Herstellung
ATE385809T1 (de) Saponin-zusammensetzungen und deren verwendung
ATE312923T1 (de) Moraxella catarrhalis basb034 polypeptide und verwendungen davon
WO2004043141A3 (en) Novel inhibin-related multiple antigenic peptide compositions that enhance production performance in avians

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee